|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM158 |
Gene summary for TMEM158 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM158 | Gene ID | 25907 |
| Gene name | transmembrane protein 158 | |
| Gene Alias | BBP | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8WZ71 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25907 | TMEM158 | C30 | Human | Oral cavity | OSCC | 3.88e-04 | 3.07e-01 | 0.3055 |
| 25907 | TMEM158 | C57 | Human | Oral cavity | OSCC | 4.12e-02 | 2.38e-01 | 0.1679 |
| 25907 | TMEM158 | SYSMH1 | Human | Oral cavity | OSCC | 3.80e-31 | 7.11e-01 | 0.1127 |
| 25907 | TMEM158 | SYSMH2 | Human | Oral cavity | OSCC | 3.99e-11 | 4.25e-01 | 0.2326 |
| 25907 | TMEM158 | SYSMH3 | Human | Oral cavity | OSCC | 3.31e-21 | 5.43e-01 | 0.2442 |
| 25907 | TMEM158 | SYSMH5 | Human | Oral cavity | OSCC | 9.33e-03 | 1.99e-01 | 0.0647 |
| 25907 | TMEM158 | ATC09 | Human | Thyroid | ATC | 1.97e-24 | 7.81e-01 | 0.2871 |
| 25907 | TMEM158 | ATC11 | Human | Thyroid | ATC | 2.02e-16 | 2.19e+00 | 0.3386 |
| 25907 | TMEM158 | ATC12 | Human | Thyroid | ATC | 2.62e-100 | 2.98e+00 | 0.34 |
| 25907 | TMEM158 | ATC1 | Human | Thyroid | ATC | 1.25e-25 | 9.23e-01 | 0.2878 |
| 25907 | TMEM158 | ATC2 | Human | Thyroid | ATC | 1.80e-12 | 7.99e-01 | 0.34 |
| 25907 | TMEM158 | ATC3 | Human | Thyroid | ATC | 2.69e-30 | 2.23e+00 | 0.338 |
| 25907 | TMEM158 | ATC4 | Human | Thyroid | ATC | 6.70e-115 | 3.37e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM158 | SNV | Missense_Mutation | c.757N>T | p.Pro253Ser | p.P253S | Q8WZ71 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM158 | SNV | Missense_Mutation | c.661N>A | p.Glu221Lys | p.E221K | Q8WZ71 | protein_coding | tolerated_low_confidence(0.08) | probably_damaging(0.979) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TMEM158 | SNV | Missense_Mutation | novel | c.662N>C | p.Glu221Ala | p.E221A | Q8WZ71 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.979) | TCGA-HU-A4GQ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |